11 Most Profitable Large Cap Stocks to Buy According to Analysts

9. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Market Capitalization: $100.708 billion

TTM Net Income: $3.64 billion

Number of Hedge Fund Holders: 60

Analyst Upside Potential: 24.75%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624.

The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the company. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered $2.96 billion during the quarter, reflecting a 12.06% increase year-over-year and ahead of expectations by $58.16 million. The EPS of $4.52 also exceeded expectations by $0.27. Management noted that this growth was driven by the successful launch of three products CASGEVY, ALYFTREK, and JOURNAVX. Moreover, its clinical programs for Suzetrigine, Zimislecel, Povetacicept, and Inaxaplin are also progressing quickly.

Looking ahead, management has reaffirmed its expected full-year revenue range of $11.85 billion to $12 billion.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company focused on developing transformative medicines for serious diseases, particularly in specialty markets.